Podcasts about approvals

In this episode of the Future Learners podcast, Brett Campbell (CEO and co-founder of Euka) and Ellen Brown (Founder and Head of Education) tackle the single most googled question they see from Australian parents every May, June and July. Can you start homeschooling in the middle of the school year? The short answer is yes, and often, the middle of the year is the smartest time to switch. Brett and Ellen walk through the seven things every parent needs to know before making a mid-year move. They cover registration timelines, what to do if your child is being bullied right now, families who are pulling kids out to travel Australia or overseas for the rest of the year, students refusing to walk through the school gate, and whether your Year 11 or Year 12 student can still finish strong with a university pathway intact. If you have been telling yourself you will “wait until next year”, this is the conversation that will help you decide whether next term, or next week, is the better answer. Key Points What the data tells us Mid-year enrolments are not the exception, they are the norm. Families join Euka every single day of the year, not only in January. 1 in 3 students now come to Euka because of bullying, up from 1 in 5 five years ago (Euka enrolment data 2021 to 2026, shared on the Today Show by Ellen Brown in April 2026). The eSafety Commissioner has reported a 37 per cent increase in actionable cyberbullying complaints from young people in the past year. Around 30 per cent of families who come to Euka mid-year do so intending to use homeschooling as a bridge, not a forever choice. Why mid-year is often a smart time to switch State education department home education units are far less swamped in May, June and July than they are in January and February. Approvals tend to come back faster outside the start-of-year peak. Your child can start at any week or term in the curriculum, in parallel with their school timeline, or by going back to the lesson where they last felt confident. Euka’s flexible learning model means you do not need to wait for a “fresh start” date that is months away to give your child a calmer week. When this episode matters for your family Your child is being bullied, and the school’s response so far has not changed it. Your child is refusing or resisting going to school, and mornings have become a battle. You are travelling for the rest of the year, around Australia or overseas, and the school calendar no longer fits. A life situation has shifted, and the 9 to 3 calendar is no longer workable. The Year 11 or 12 timetable is breaking your student, and you have been told “they cannot leave now”. You have been thinking about homeschooling for a while, and you are tired of waiting for January. The Single Most Asked Question We Hear Every May, June and July Every year, the same question lands in the Euka inbox in waves. Some version of “is it too late to start now?”, or “can I switch in the middle of the year?”, or “do I have to wait until Term 1 next year?”. The answer has not changed, and it is short. No, it is not too late. Yes, you can switch right now. You do not have to wait. What has changed is the number of families asking, and the range of reasons. Bullying is the biggest single trigger, but the same conversation comes from families heading off to travel for the rest of the year, parents whose child has stopped getting in the car for school, and senior students whose Year 11 or 12 timetable has stopped working. “You do not have to wait for January. Often, the next term is too late. The decision to remove a child from a situation that is hurting them is not a decision that should sit on a shelf.”— Ellen Brown, Founder and Head of Education, Euka 7 Things to Know Before You Switch Mid-Year This is the spine of the episode, structured as a journey from the first moment of doubt, to the decision, to the first day at home. 1. You can start any day of the year There is no enrolment cliff at the end of January. The Euka program is built so that a student can begin at any lesson, in any week, in any term. If your child is in the middle of Term 2 at school, they can pick up at the equivalent point in the Euka curriculum, or go back to where they last felt on top of the work and rebuild from there. 2. Mid-year is actually a faster registration window State home education units process the bulk of their applications between November and February. By the middle of the year, the queue is shorter and the wait times are better. If you are looking at homeschooling in New South Wales, Queensland, Victoria or any other state, mid-year is the calmer side of their admin calendar. 3. You do not need the school principal’s permission This is the line Ellen comes back to most often. Parents have the legal authority to remove their child from a school and educate them at home. You notify the principal, you do not ask permission. If your child’s safety is at immediate risk, you can remove them straight away while the formal registration is being processed. A medical or psychologist certificate can support that step. 4. Your child will not fall behind, and the “gap” often helps Euka delivers the same state-based curriculum as your child’s school, mapped to the Australian Curriculum and the relevant state syllabus. Lessons are designed to be picked up at any point. There is a thing Ellen calls “the gap” that matters here. When a child is in a stressful situation at school, the stress snowballs and the schoolwork in front of them stops going in. They are already falling behind, even while they are sitting in the classroom. Taking them out of that environment, even briefly, gives them the space to reset and regain composure. You are a product of your environment, and changing the environment changes the outcome. Many families find their child actually moves ahead once the day is built around how they learn best. 5. Year 11 and 12 students can switch too This is the one parents are most afraid of, and it is the one that almost always surprises them. In a traditional school, jumping out of Year 11 or 12 mid-year feels final. With Euka, it is not. The senior pathway recognises prior work, the assessment model uses upload-feedback-resubmit so students keep building their academic record, and Euka’s University Pathways include a partnership with Navitas that opens entry into more than 90 university colleges in Australia, the UK, Canada and the USA, without an ATAR. “I was that parent that was worried, like, what about after? But my eldest has received a conditional offer to law, and she is knocking it out of the park.”— Barbara Bryan, Euka parent, Episode 43 6. If safety is at risk, you can act immediately The bullying numbers are why this point matters. One in three students now come to Euka because of bullying, and actionable cyberbullying complaints to the eSafety Commissioner have risen 37 per cent in the past year. When the situation has become unsafe, the decision to remove your child is a today decision. The registration can happen in the background while your child gets the space to recover. 7. You will not be the teacher The fear that holds the most parents back is the fear that they will have to become a maths teacher, a science teacher, an English teacher, all at once. They will not. The lessons are written and delivered by qualified teachers through the Euka platform; the parent’s role is to facilitate, not to instruct. You sit alongside your child, not in front of a whiteboard. Answered Questions Real questions Australian parents ask, answered through the practical experience of running Euka and supporting families through mid-year switches. Can I start homeschooling in the middle of the school year? + Yes. The Euka program is built to be started at any point in any term, and families enrol every day of the calendar year. There is no waiting until January, and no “missed window”. “You do not have to wait for January. You can just jump on into homeschooling, and it is going to adjust around you and adjust around your child.”— Ellen Brown The state-based registration runs faster mid-year because the home education units are not as swamped as they are at the start-of-year peak. If safety is the reason you are moving now, your child can begin at home while the formal paperwork is being processed. How do I register for homeschooling in New South Wales, Queensland or Victoria? + Every state runs its own home education registration process, and the requirements vary. Euka’s Registration Service was built to remove the guesswork. You fill out a short questionnaire, Euka prepares the documentation including the individualised curriculum learning plan, and you submit it to your state’s home education unit. “We had families spending weeks navigating department websites and trying to write their own education plan from scratch. We built the Registration Service so a parent could go from ‘I want to do this’ to ‘my application is in’ in days, not weeks.”— Brett Campbell, CEO Euka Future Learning The state-specific pages walk through what your state expects: homeschooling in NSW, homeschooling in Queensland, homeschooling in Victoria, and the full set sits on the Why Homeschool hub. Is it too late to start homeschooling in Year 11 or Year 12? + No. Year 11 and Year 12 are the years parents assume they cannot move out of, and it is the assumption that holds the most families back unnecessarily. Senior students who switch to Euka keep their prior academic work, continue building their transcript through the assessment program, and have access to Euka’s University Pathways. “The pathway concern is the one that worries every parent. It is also the one that has the clearest answer. There are now more than 90 university colleges in Australia, the UK, Canada and the USA that accept our graduates through the Navitas partnership, without an ATAR.”— Brett Campbell For students who are not sure whether they want university, Ellen’s standard advice is to do the assessed pathway anyway, so the academic transcript exists if the decision changes later. What if my child is being bullied at school, do I need permission to leave? + No, you do not need the principal’s permission. Parents have the authority to withdraw their child and educate them at home; you notify the school, you do not ask. If the situation is unsafe, you can act immediately and complete the formal registration in parallel. The reality of bullying in Australian schools has shifted: one in three students who join Euka cite bullying as the reason, and the eSafety Commissioner reports a 37 per cent rise in actionable cyberbullying complaints in the past year. “If you do not see any signs of the school or the education department working to fix the problem, get out. I regret every day of those six months.”— Barbara Bryan, Euka parent, Episode 43 Can homeschoolers still get into university without an ATAR? + Yes, and the pathway is well established. Euka’s senior students build an academic transcript through an upload-feedback-resubmit assessment model. That transcript, combined with a university entry or foundation course, gives them access to more than 90 university colleges through the Navitas partnership, including in the UK, Canada and the USA. For students aiming at competitive degrees like law or medicine, this is a real, established route. For students who are unsure, doing the assessed pathway keeps the door open. How long does it take to switch from school to homeschooling with Euka? + Faster than most parents expect. The first practical day at home can be the day you decide; the formal registration runs in the background. Euka’s Registration Service typically prepares the documentation in days, and mid-year submissions tend to be processed faster than start-of-year ones because the state units are not as overloaded. The biggest delay is rarely the paperwork. It is the decision itself. Why This Episode Matters Mid-year is not a compromise, it is often the better window. If the school year started badly, or if something has changed for your family in the last few months, you do not have to ride it out until January. The state systems are calmer, the curriculum picks you up where you are, and the gap between deciding and starting can be days. Year 11 and 12 are not closed doors. The line that “they have to stay in school to finish” is the most common misconception we hear. Senior students switch to Euka mid-year, keep building their transcript, and walk into university through Euka’s University Pathways without needing an ATAR. Safety is a today decision. With bullying behind one in three Euka enrolments, and cyberbullying complaints up sharply, the choice to act is rarely about “if”. It is about how fast. Your Family, Your Journey If you have been wondering whether you have left it too late, you have not. Mid-year families start with Euka every week of the term, and most look back wishing they had started sooner. The post Can I Start Homeschooling in the Middle of the School Year? | 044 appeared first on Euka.

Have you ever wondered why Capital One's approval decisions feel completely random - approval for some, denial for others, with almost no rhyme or reason?   Capital One has a well-earned reputation for being unpredictable with credit card approvals. When Katie from Katie's Travel Tricks saw the launch of the new Capital One Business Venture card, she decided to move beyond anecdotes and collect real data. She surveyed her audience about their approval and denial experiences, gathered nearly 150 responses, and analyzed the patterns using data to answer the questions everyone has been asking: what actually matters to Capital One?   Katie and I break down what her data revealed about the three strongest approval predictors, why the conventional wisdom about waiting six months between Capital One applications might not be accurate, which metrics matter (credit score, hard inquiries, pre-approval status) and which ones surprisingly don't, and how business structure (sole proprietor versus LLC) impacts your approval chances. We also discuss what role the Capital One Business Venture Card plays in your overall rewards strategy and how to think about it within the larger Capital One ecosystem.   Get full show notes and transcript: https://pointmetofirstclass.com/capital-one-approvals-data       Eager to learn the secrets of award travel so that you can turn your expenses into unforgettable experiences? Join the Points Made Easy course waitlist here: https://pointmetofirstclass.com/pointsmadeeasy  

While most investors have been rattled by the tax overhaul, the biggest risk right now isn't the budget itself, but how lenders are reacting to it, with pre-approvals increasingly unreliable and buyers at risk of being caught mid-deal. On The Smart Property Investment Show, Phil Tarrant speaks with Eva Loisance, principal at Finni Mortgages, about the post-budget lending shake-up and what it means for investors trying to secure finance in an increasingly unpredictable environment. Loisance explains that pre-approvals are no longer a safe assumption, with some lenders already stripping out negative gearing from servicing models while others hold the line pending clearer legislation. She warns the real impact is already hitting borrowing power, with modelling showing some dual-income households could lose close to 30 per cent in lending capacity if servicing rules fully exclude negative gearing benefits. As uncertainty flows through the system, lenders are tightening conditions, reassessing risk, and quietly reshaping what investors can actually borrow – well before any law is finalised. The episode also explores how investors may pivot, including a shift toward new-build stock that retains tax treatment advantages, despite higher costs limiting feasibility for many. Loisance flags potential flow-on effects into the rental market, with investors forced to chase yield more aggressively as tax efficiency is stripped back and holding costs rise. If you like this episode, show your support by rating us or leaving a review on Apple Podcasts and by following Smart Property Investment on social media: Facebook, X (formerly Twitter) and LinkedIn. If you would like to get in touch with our team, email editor@smartpropertyinvestment.com.au for more insights, or hear your voice on the show by recording a question below.

Summary: In this episode of the Ops Experts Club podcast, Aaron Hovivian and Terryn Turner unpack one of the most overlooked areas in business operations: vendor payments, contract management, and approval systems. They dive into the dangers of blindly paying invoices without proper checks and balances, sharing real examples of businesses that were unknowingly exposed to duplicate billing, disorganized contracts, and financial inefficiencies. From contract repositories and approval workflows to task management systems and AI-powered organization, the conversation breaks down practical ways operators can protect growing businesses from costly mistakes. Aaron and Terryn also explore the important role operations leaders play between finance, bookkeeping, HR, and leadership teams. They discuss why visionary entrepreneurs often need structured operational support, how trust and accountability are built within approval systems, and why organized documentation becomes critical as companies scale. Whether you're running a small online business or managing a fast-growing team, this episode offers actionable systems and operational insights to help you tighten up your backend processes and create better financial oversight. To learn more about operational audits, bookkeeping systems, and financial process support, visit Finance.TheCollabTeam.com Minute by Minute 00:00 Welcome to Ops Experts Club 01:20 The Importance of Systems in Online Business 02:16 Managing Contracts and Payments 04:57 Organizing Contracts and Approvals 09:15 Creating a Contract Repository 11:06 Approval Processes in Finance 14:40 Managing HR and Contractor Agreements  

Dive into the latest episode of Pharmacy Friends for a discussion of the FDA Commissioner's National Priority Voucher pilot. While accelerated approvals may improve access to innovative therapies, what could a compressed decision-making window mean for evidence review, affordability assessment and implementation planning? Prime experts Angela Sutton and Bob Greer explore the important roles clinical confidence and operational readiness will play in making solid coverage decisions. Hear what they're most focused on, including:Managing drug spendAssessing coverage strategiesDetermining policy risk00:00 Introduction02:10 What's generating all the questions now?04:35 FDA Hearing05:50 Pro's and con's of accelerated drug approvals11:05 Policy uncertainty and impact to payers11:54 Impact of FDA leadership changes12:24 Meeting the moment15:26 Using data to make better decisions that need to be fast18:39 What we would tell the acting FDA leadership that matters23:15 Closing

Many row crop farmers are concerned about having access to an array of crop protection tools. EPA Administrator Lee Zeldin explains the shrinking backlog of approvals, how the agency will continue to engage with the Make America Healthy Again movement, and year-round E15. Plus, Mitchell Hora with Continuum Ag outlines the testimony he gave on the 45Z Clean Fuel Production Tax Credit and Megan Boutwell with Stillwater Associates discusses how state low carbon fuel standards are shifting demand for ag products.Want to receive Newsmakers in your inbox every week? Sign up! http://eepurl.com/hTgSAD

Kia ora. Welcome to Friday's Economy Watch where we follow the economic events and trends that affect Aotearoa/New Zealand. I'm David Chaston and this is the international edition from Interest.co.nz. Today we lead with news the US and Iran have apparently agreed a 60 day truce, pending Trump's signoff. All the while, both sides traded attacks in the region. The small number of ships transiting the Strait of Hormuz has virtually dried up. Meanwhile, US jobless claims slipped last week to 185,600 and by about what seasonal factors would have indicated. There are now 1.68 mln people on these benefits, less than one and two years ago. There was a sharp drop in new home sales reported for April, and they were -11.3% lower than year ago levels. Rising mortgage rates is weighing heavily on this sector. But they reported a sharp increase in durable goods orders in April, up +19% from a year ago, up notably from March. This is where we see the full effect of stockpiling as buyers try to get ahead of rising inflation. One reason was a +41% jump in capital goods on the same basis. But excluding defense and aircraft orders, the increase was modest. The second estimate of GDP growth for Q1-2026 is out and it was revised lower, mainly on lower consumer spending and investment levels than in the initial estimate. They now say the US economy expanded +1.6% in the period. They also released the April data for US personal income and personal spending. This showed that personal disposable income fell from March, up +2.5% from a year ago, while personal consumption expenditures rose, up +5.9% from a year ago. In fact, their April PCE inflation measure rose to 3.8%, its highest since May 2023 and the end of the pandemic effect, and prior to that the highest since this data was collated in 2017. Undoubtedly, this has the Fed's attention, especially the accelerating nature of it. US crude oil and petrol stocks fell again last week, but 'only' by about the levels expected. that extends the fall to five consecutive weeks, all substantial, and coming after three prior weeks of modest or no-change outcomes. Retail pump prices for petrol are still +48% higher than at the start of the Iran-US conflict and closure of the Strait of Hormuz. There was a US Treasury 7yr note auction overnight and the yield increase was not as fierce as yesterday's event. This one delivered a median yield of 4.24% (high 4.29%), up from the 4.12% at the prior equivalent event a month ago. In Canada, their central bank has released and updated Financial Stability Report which found that Canada's financial system has functioned well through a challenging year. Households and businesses remain in stable financial condition, and banks have strengthened their capacity to absorb shocks. Meanwhile they reported that average weekly earnings rose +3.5% in March from a year ago, a faster pace of increase. They have CPI inflation of +2.8% at the same time so Canadian employees are generally staying ahead of the cost pressures. The Korean central bank kept its official rate unchanged yesterday at 2.5%, as expected. Updated Australian household spending data for April shows it fell -1.1% month-on-month (on a current price, seasonally adjusted basis) to be +4.9% higher than in April 2025. In the same period CPI inflation rose 4.2%. The weak outcome is being attributed to the sharp hike in fuel costs, and compensating pullbacks elsewhere. It is their first fall in household spending in four months. And staying in Australia, they said private new capital expenditure rose +6.5% in the March quarter to be +14.6% higher than the March 2025 quarter. This strong growth is largely on the back of significant investment in data centers, up +96% and a new record high. Investment in mining was flat. The Middle East war lead to a -3.4% fall in air passenger demand in April. But Asia/Pacific international demand rose +3.0% from a year ago. For air cargo, demand was up +4.0% despite the turmoil, up +11.3% in the Asia/Pacific region. Global container shipping freight rates rose +3.2% last week from the prior week to be +12% higher than year-ago levels. This is largely driven by rates from China to the EU. Transpacific rates from China to the US West Coast actually fell last week. As did trade volumes. Meanwhile bulk cargo rates rose +4.4% last week, to be a massive +140% higher than a year ago. The UST 10yr yield is now just on 4.45%, down -3 bps from this time yesterday. The price of gold will start today up +US$57 at US$4506/oz. Silver is back up +US$1.50 at just under US$76/oz. Oil prices have fallen -50 USc to just on US$89/bbl in the US, while the international Brent price is now at US$93.50/bbl and down -US$1.50/bbl. The Kiwi dollar is up +40 bps from yesterday at this time at 59.3 USc. Against the Aussie we are up +20 bps at 82.8 AUc. Against the euro we are also up +20 bps at just under 50.9 euro cents. That all means our TWI-5 starts today at just under 62.8 which is up +40 bps from yesterday. The bitcoin price starts today at US$73,455 and down -1.8% from this time yesterday. Volatility over the past 24 hours has been moderate at just under +/- 2.0%. You can get more news affecting the economy in New Zealand from interest.co.nz. Kia ora. I'm David Chaston and because Monday is a New Zealand holiday, we'll do this again on Tuesday.

#280: Learn how to dramatically improve your odds of getting approved for the credit cards you actually want. Chris breaks down the hidden system every bank uses to evaluate applications, why your credit score matters far less than what's on your report, and the real factors driving denials, from credit-to-income ratios to recent inquiries to each issuer's internal model. He also walks through what to do before you apply, how to sequence applications across issuers, and the right moves to make after a denial. Link to Full Show Notes: https://chrishutchins.com/credit-card-approval-strategy. Partner Deals Quince: Affordable luxury essentials with free shipping + 365 day returns Mercury: Help your business grow with simplified finances Wispr Flow: ⁠Try effortless voice dictation for free Fabric: ⁠Affordable term life insurance for you and your family LMNT: ⁠Free sample pack of my favorite electrolyte drink mix For all the deals, discounts and promo codes from our partners, go to: ⁠chrishutchins.com/deals Resources Mentioned Credit Cards The Atmos™ Rewards Visa Summit Card The Business Platinum Card® from American Express Southwest Rapid Rewards® Plus Credit Card Capital One Venture X Business Capital One Venture X Rewards Credit Card Capital One Spark Cash Plus Tools & Resources Doctor of Credit MyFICO Forums LexisNexis Articles Complete Guide to Credit Card Application Rules by Bank ATH Podcast #221: Deep Dive on Credit Reports, Scores, and Their Real-World Impact #228: Deep Dive on Citi Credit Cards and ThankYou Points (Best 2-Card Combo) #236: Deep Dive on Amex Credit Cards and Membership Rewards Points #242: Deep Dive on Capital One Credit Cards and Miles (+ Why I Love Them) #247:Deep Dive on Bank of America Credit Cards (Up to 5.25% Cash Back) Best Cards Page AMA: Submit A Question Newsletter Leave a review: Apple Podcasts | Spotify Email for questions, hacks, deals, and feedback: podcast@chrishutchins.com Full Show Notes (00:00) Introduction (03:50) Why Chris Lets His Cards Report High Balances (05:06) When Your Credit Score Actually Matters (05:53) Why Business Cards Stay Off Your Credit Report (06:39) What Actually Counts as a Business (10:55) How Your Credit-to-Income Ratio Drives Approvals (14:48) What Your Payment History Reveals (15:08) Why Recent Inquiries Can Sink Your Application (17:44) The Chase 5/24 Rule Explained (18:44) The Hidden Internal Models Banks Use (19:18) Diagnosing a Listener's Surprise 820-Score Denial (24:56) What to Check Before You Hit Submit (25:55) Sequencing Business Card Applications for Approval (28:05) The Best Personal Card Offers Right Now (28:50) Why a Checking Account Can Boost Your Odds (30:10) Using Frozen Credit Bureaus to Your Advantage (32:37) Tag-Teaming Applications With a Partner (33:32) Why Last-Minute Fixes Don't Work (34:32) Using Pre-Qualification Tools to Avoid Hard Pulls (34:49) Cutting Unnecessary Credit to Get Approved (35:27) What Actually Happens After a Denial (40:54) When It Makes Sense to Close a Card (44:26) The Hidden Value of Card-Linked Offers (46:15) Every Major Bank's Application Rules (48:45) The Mindset Shift That Changes Everything Connect with Chris ⁠⁠Newsletter⁠⁠ | ⁠Membership⁠⁠ | ⁠X⁠⁠ | ⁠Instagram⁠⁠ | ⁠LinkedIn⁠⁠ Editor's Note: The content on this page is accurate as of the posting date; however, some of our partner offers may have expired. Opinions expressed here are the author's alone, not those of any bank, credit card issuer, hotel, airline, or other entity. This content has not been reviewed, approved or otherwise endorsed by any of the entities included within the post. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode I discuss bioequivalence testing and how it was developed to support generic drug approvals, but is now a mainstream tool for all of drug development. I discuss the basics of what bioequivalence means, how the studies are designed, and then how to perform the statistical analysis. I end with some examples of how this can be used for both generic drug and innovator drugs to support labeling. Links discussed in the show:FDA Draft Guidance: Statistical Approaches to Establishing Bioequivalence (Dec 2022) – Excellent detail on methods, models, and SAS examples. FDA Guidance: Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA. Article: “Bioequivalence of generic drugs: a simple explanation for clinicians” (Andrade, 2015) – Great for the 80-125% intuition. R-script with example BE analysis (Be sure to copy this text into a file and name it "BE-example.R" then you can run it on your local R instance.You can connect with Nathan on LinkedIn and send me a message Send Nathan a message Sign up for Nathan's newsletter Copyright Teuscher Solutions LLCAll Rights Reserved

The Tim Conway Jr. Show Hour 1 (5.20) It’s the Wednesday before Memorial Day weekend and people are already starting to get out of town. But many plans have changed because of the wildfires in Simi Valley and Ventura County. Is it air purifier season? And it’s the last Memorial Day to hang out at Primm before the resort closes forever! Are you going to the beach for Memorial Day weekend? If so, for heaven’s sake do not pick Santa Monica, because the area around Santa Monica Pier ranks No. 1 as the dirtiest beach in California. If you live in Rancho Palos Verdes, it’s a nightmare to undergo home renovations because you’re at the mercy of overly restrictive regulations. Approvals are often costly and unnecessary, and many homeowners just give up. And if they draw attention to it, they may face repercussions from the Palos Verdes Home Association & Art Jury. See omnystudio.com/listener for privacy information.

Today – Mansfield’s push to bring Buc-ee’s to the I-71 and Ohio 39 interchange took a major step forward this week, but the project still has a few more approvals ahead.Support the show: https://richlandsource.com/membersSee omnystudio.com/listener for privacy information.

Shannon Joseph, chair of Energy for a Secure Future, says Canada is finally moving from endless debate toward clearer rules and timelines around major energy infrastructure — but warns investor confidence, Indigenous buy-in, and legal risks will ultimately determine whether a new bitumen pipeline actually materializes. She argues Canada's LNG sector offers a roadmap for how oil projects can succeed through regulatory certainty, faster approvals, and Indigenous ownership models.Energy for a Secure Future is a member of The Hub's Corporate & Industry Council.The Hub is Canada's fastest growing independent digital news outlet. Subscribe to The Hub's podcast feed to get all our best content:https://tinyurl.com/3a7zpd7e (Apple)https://tinyurl.com/y8akmfn7 (Spotify)Watch a video version on YouTube: https://www.youtube.com/@TheHubCanadaFollow The Hub on X: https://x.com/thehubcanada?lang=en CREDITS:Elia Gross - Producer and Sound EditorAmal Attar-Guzman - Video Editor Falice Chin - Host Hosted on Acast. See acast.com/privacy for more information.

On this episode of Closed!, Lee Bergstein is joined by Mark Levine, Principal at EBMG LLC, Accredited Property Management LLC, and Apex Management Group—one of New York City's most active property managers, overseeing hundreds of co-op and condominium buildings across the city. Together, they break down one of the most frustrating and opaque parts of NYC real estate: the co-op board application process.From incomplete applications and internal board dynamics to the real reasons deals get delayed or denied, Mark offers a behind-the-scenes look at how these decisions are actually made—and where things most often go wrong. The conversation also dives into the upcoming legislation imposing strict timelines on board approvals, what it means for buyers, sellers, and boards, and whether it will truly fix the system or just create new challenges.Co-op approvals can make or break a deal—and they impact everyone involved. In this episode, Lee and Mark unpack the pain points, the pressure, and the potential reforms shaping the future of NYC real estate transactions.If you love law, real estate, or New York City, then this is an episode for you.To learn more about Mark Levine and his companies, visit: http://www.manageyourbuilding.com/ or ebmg.com. To find out more about Bergstein Flynn Knowlton & Pollina PLLC, visit our website at bfkplaw.com. Hosted on Acast. See acast.com/privacy for more information.To find out more about Bergstein Flynn Knowlton & Pollina PLLC, visit our website at bfkplaw.com. Hosted on Acast. See acast.com/privacy for more information.

See omnystudio.com/listener for privacy information.

John Highley breaks down what it actually looks like inside a PDR shop once the hail hits. This episode is straight shop talk—insurance delays, adjuster issues, storage strategy, approvals, and how to keep jobs moving when everything is backed up and chaotic. If you've worked a storm, you already know… this is where the real game starts.

Conservative energy critic Shannon Stubbs; The Front Bench with Christy Clark, Marco Mendicino, James Moore and Tony Clement; Brian Kingston, President and CEO of the Canadian Vehicle Manufacturers' Association; A live press conference with B.C. Premier David Eby; CTV Ottawa Bureau Chief Graham Richardson.

Updated information on two USDA assistance programs. Under Secretary for Farm Production and Conservation starts first with the Farm Bridge Assistance Program.

If your write-up is weak… your paycheck is leaking. Period. In this episode, I'm going straight at one of the most overlooked, but most expensive breakdowns in your service department: the quality of your RO write-up. We're talking about the real impact of vague notes, rushed conversations, and missed questions and how they quietly destroy technician productivity, create comebacks, slow down approvals, and chip away at your income. I break down exactly how to level up your write-up process, what questions actually matter, and how to position yourself as the translator between your customer and your technician. This is one of those "simple but not easy" skills that separates average advisors from top earners. Better notes = faster diagnosis, smoother workflow, stronger trust, and more money in your pocket. If you're ready to clean up the chaos and take control of your lane… this is your play. Dealer Talk with Jen Suzuki Podcast |

Greek golden visa approvals jumped nearly 96% in 2025, and the government just dropped a 31-page circular targeting fake deals fueling the boom. In this video, you'll learn the new fraud rules, the €250,000 option that survives, and why the Airbnb ban is narrower than the headlines suggest.Read the full story here.

The federal government says demand for parent visas will always outstrip Australia's capacity to grant them. With places capped at 8,500, high demand continues to drive long waiting times. Assistant Minister for Citizenship, Customs and Multicultural Affairs Julian Hill says the government has increased the number of visas granted and is open to considering changes. In this podcast, we speak to an Indian Australian Sunita Kalkal who says the long wait is difficult and is urging the government to develop new policies.

A new private member's bill is proposing to speed up the approval of agricultural products in Canada by relying more heavily on decisions made in other countries. Bill C-273, the Facilitating Agricultural Regulatory Modernization Act, would amend several federal laws, including the Feeds Act, Fertilizers Act, Seeds Act and Pest Control Products Act. It proposes a system allow products already approved in at least two "trusted jurisdictions" to receive provisional approval in Canada within 90 days of a complete application. The bill, introduced by Conservative MP for Bow River, Alberta, David Bexte, defines "trust jurisdictions" as foreign governments or regions designated through regulation. That could include jurisdictions like the EU, the U.K., the U.S., Australia, and New Zealand.

Welcome and thanks for tuning in to this mid-week edition of RealAg Radio with your host Shaun Haney, brought to you by FMC Ag Canada! On today’s show, Haney is joined by: Kelvin Heppner of RealAgriculture to discuss the Conservative Private Members' Bill; Bryan O'Hara of FMC Ag Canada for a spotlight interview; USDA Deputy... Read More

Welcome and thanks for tuning in to this mid-week edition of RealAg Radio with your host Shaun Haney, brought to you by FMC Ag Canada! On today’s show, Haney is joined by: Kelvin Heppner of RealAgriculture to discuss the Conservative Private Members' Bill; Bryan O'Hara of FMC Ag Canada for a spotlight interview; USDA Deputy... Read More

WBBM political editor Geoff Buchholz reports on a proposal that could speed up approval for legal video gambling terminals in Chicago bars and restaurants.

WBBM political editor Geoff Buchholz reports on a proposal that could speed up approval for legal video gambling terminals in Chicago bars and restaurants.

WBBM political editor Geoff Buchholz reports on a proposal that could speed up approval for legal video gambling terminals in Chicago bars and restaurants.

Brisbane's housing shortage isn't just about supply it's about what's actually making it to completion. In this episode, we unpack the real issue behind the numbers, including: The widening gap between approvals, construction, and completed homes Why many approved projects never get built How rising construction costs and feasibility challenges are slowing supply What current demand and population growth mean for housing pressure in Brisbane How buyer behaviour is shifting in today's market The flow-on effect this imbalance is having on property prices heading into 2026 If you're planning to buy or invest in Brisbane, this episode will help you understand what's really happening behind the headlines — so you can move forward with clarity and confidence.   Connect with Us: Listen on Apple Podcasts https://podcasts.apple.com/us/podcast/brisbane-property-podcast/id1509129258 Listen on Spotify https://open.spotify.com/show/5tODCtY54iQrxadNqqmevs Subscribe on Youtube https://www.youtube.com/channel/UCW30uBCnHQ2YllnwGKHNfxg Streamline Property Buyers Website https://streamlineproperty.com.au/ Ready to work with us directly? https://streamlineproperty.com.au/contact/   If you liked this episode, please don't forget to subscribe, tune in, and share this podcast with others you know will benefit from the information we share!

Biogen, Eli Lilly and Merck spent more than $20 billion in the past week to swallow biotechs with approved products or promising drug candidates—representing three of this year's four biggest takeovers. First, Merck picked up Terns Pharmaceuticals and its mid-stage leukemia drug for $6.7 billion. Then, on Tuesday, Lilly and Biogen struck, acquiring Centessa Pharmaceuticals and Apellis Pharmaceuticals respectively.Those big-ticket deals aren't the only recent transactions, however. Others include Novartis' up to $2 billion pick up of Excellergy and Gilead's $2.1 billion purchase of Ouro Medicines. Meanwhile, Kevin Tang—the newly minted CEO of Aurinia Pharmaceuticals—again has his sights set on Kezar Life Sciences, which he previously targeted in 2024. This time, biopharma's “clean-up” man is offering $50 million for the chronic disease–focused biotech.Last week also saw nods for Denali Therapeutics' Avlayah, the first treatment for Hunter syndrome to target the disease's neurological complications, and Rocket Pharmaceuticals' Kresladi for leukocyte adhesion deficiency-I. And it's been a big week for Biogen, which besides moving on Apellis, won approval of a high-dose formulation of spinal muscular atrophy drug Spinraza and scored a Phase 2 win for lupus candidate litifilimab in cutaneous lupus erythematosus.On the weight loss front, Wave Life Sciences' stock was cut in half after its obesity candidate WVE-007 failed to impress investors in a Phase 1 trial.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the fast-paced changes shaping these sectors, focusing on the latest scientific breakthroughs, regulatory shifts, and industry trends.First off, Denali Therapeutics has achieved a significant milestone with FDA approval for its enzyme replacement therapy targeting Hunter syndrome, a rare genetic disorder. This therapy addresses neurological complications that have been challenging to treat, marking a pivotal moment for the rare disease community. Hunter syndrome is characterized by enzyme deficiencies leading to harmful accumulations in the body. The availability of this treatment not only provides new hope for patients but also underscores the potential of targeted therapies to manage complex neurological symptoms effectively.In oncology, Corcept Therapeutics has secured FDA approval for Lifyorli (relacorilant), designed for platinum-resistant ovarian cancer patients who have already undergone multiple lines of systemic treatment. This approval highlights the critical importance of strategic clinical trial design and persistent regulatory engagement, expanding treatment options for a patient population with limited alternatives.Meanwhile, Ionis Pharmaceuticals made headlines by slashing the annual price of Tryngolza by 93% ahead of its intended label expansion for severe hypertriglyceridemia. This strategic move aims to make the drug more accessible and capture a broader market share while addressing pricing pressures from regulators and patients alike. Such pricing strategies might set new precedents in the industry, particularly for drugs initially developed for rare diseases now targeting more common conditions.The funding landscape presents challenges as biopharma investment has dropped 20% in 2025. Companies are now prioritizing high-impact projects over broader portfolios, reflecting a shift towards focused R&D investments. This cautious climate may accelerate breakthroughs in prioritized areas yet poses risks if diversification is neglected.Regulatory dynamics are also in flux. The departure of Dr. Robert Malone from the CDC's Advisory Committee on Immunization Practices highlights ongoing tensions within vaccine advisory panels. These developments underscore the intricate balance between scientific evidence, public health policy, and stakeholder communication in guiding vaccine-related decisions.Technological advancements continue to reshape operations within life sciences companies. AI-driven platforms are playing a vital role in enhancing Medical-Legal-Regulatory processes by offering adaptable solutions that transcend traditional automation limits. This innovation is crucial for organizations aiming to optimize regulatory compliance while maintaining operational efficiency.In medical devices, Philips' AI-powered cath lab copilot has gained FDA clearance in collaboration with Edwards Lifesciences. This technology assists in transcatheter mitral valve repair—a complex procedure requiring precision and real-time data analysis—illustrating how AI can significantly enhance procedural outcomes and patient safety.Shifting focus to genetic therapies, Beam Therapeutics has shown promising progress with its base editing technology for alpha-1 antitrypsin deficiency (AATD), potentially revolutionizing treatment approaches for genetic disorders. Similarly, Sarepta Therapeutics is advancing RNA-based treatments with positive biomarker data for muscular dystrophies, reinforcing RNA therapies as viable alternatives or complements to traditional gene therapies.However, not all news is positive. Wave Life Sciences faced a setback when its obesity drug candidate showed only a modest reduction in body weight over six months. This highlights the competitive pressures and high expectations within metabolic disoSupport the show

Learn why most content approval bottlenecks in financial firms are actually design problems, not compliance issues. Hear how risk-tiered workflows, automated systems, and centralized repositories can accelerate approvals while strengthening your regulatory posture. Financial Media Exchange, LLC City: Plymouth Address: 100 Court St. Website: https://www.fmexc.com/

3,172 approvals and nearly US$1B in deposits and property; MM2H's rebound from its disastrous 2021 overhaul is now quantifiable.View the full article here.Subscribe to the IMI Daily newsletter here. 

It's In the News, a look at the top headlines and stories in the diabetes community. This week's top stories: Metformin may help stem macular degeneration, retatutride moves forward, T1D and demntia link studied, lots of news from ATTD and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  transcript with links:  Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Who's in Vegas? I'll see you there at the Breakthrough T1D summit this weekend. And we have two Club 1921 events for health care providers and patient leaders happening in April – head on over to the website for more. Okay.. our top story this week: XX Metformin may be linked to the slower progression of age-related macular degeneration (AMD). Among people with diabetes who were older than 55, those taking metformin had a 37% lower chance of developing intermediate AMD over a five-year period compared with individuals who were not using the medication. It's one of the leading causes of vision loss in the US and many other western countries. These researchers now say a clinical trial is the next step. https://scitechdaily.com/scientists-discover-surprising-eye-benefit-of-widely-used-diabetes-drug/ XX new study suggests people with type 1 diabetes may be nearly three times as likely to develop dementia compared with people without diabetes. Similarly, people with type 2 diabetes may have roughly twice the risk of dementia compared with those without diabetes. However, the study found an association rather than proof of causation, meaning diabetes was linked to dementia risk but was not shown to directly cause it.   https://www.usnews.com/news/health-news/articles/2026-03-19/both-types-of-diabetes-increase-dementia-risk XX Researchers in Japan say they've developed an insulin pill… in mice.  The study, published in the journal Molecular Pharmaceutics, tested the delivery of oral insulin by building a carrier peptide called DNP-V. This peptide helps to transport insulin through the small intestine, where protein drug absorption is usually poor. The result was a rapid and significant drop in blood glucose, as well as a sustained (longer-term) decrease. The mice's blood sugar was reduced to near-normal levels. Although the researchers are optimistic about the findings translating to larger therapeutic models, they noted that the results in mice do not guarantee the same outcome in humans, and that more research is needed. https://www.foxnews.com/health/needle-free-diabetes-management-could-horizon-study-suggests   XX   Lilly says it's next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients. The drug lowered hemoglobin A1C by an average of 1.7% to 2% across different doses at 40 weeks compared with placebo, and helped patients lose an average of 16.8% of their weight. Retatrutide also met the study's second goal, helping patients at the highest dose lose an average of 16.8% of their weight, or 36.6 pounds, at 40 weeks, when evaluating only patients who stayed on the drug. When analyzing all participants, including those who discontinued treatment, the highest dose of the drug helped patients lose 15.3% of their weight. The company was also "very pleased" with the relatively low discontinuation rates due to side effects, which were up to 5%, he added. But Lilly has yet to file for approval of the drug for obesity or diabetes. The company expects to report findings from seven additional phase three trials on the drug by the end of the year. Still, retatrutide's A1C reduction doesn't appear to be the greatest Lilly has seen within its portfolio: The highest dose of Zepbound lowered the measure by more than 2% at 40 weeks in two separate trials on diabetes patients. Dubbed the "triple G" drug, retatrutide works by mimicking three hunger-regulating hormones – GLP-1, GIP and glucagon – rather than just one or two like existing treatments. That appears to have more potent effects on a person's appetite and satisfaction with food than other treatments.   https://www.cnbc.com/2026/03/19/eli-lillys-obesity-drug-retatrutide-clears-late-stage-diabetes-trial.html XX   The MiniMed Flex gets FDA approval. Thi is a new design from the company formerly known as Medtronic. It's about half the size* of the MiniMed™ 780G pump, no screen – smartphone controlled – and has the SmartGuard™ algorithm with Meal Detection™ technolog. At commercial launch, MiniMed Flex™ will support the company's newest sensor portfolio, including Simplera Sync™ sensor and the Instinct sensor, made by Abbott. MiniMed also announced the MiniMed™ Forward Program, which allows customers who start on the MiniMed™ 780G system to upgrade to the MiniMed Flex™ system for $0. MiniMed Flex™ is cleared for individuals ages 7 and older with type 1 diabetes, and for individuals 18 years and older with insulin-requiring type 2 diabetes. https://www.prnewswire.com/news-releases/minimed-announces-fda-clearance-of-minimed-flex-the-companys-smallest-insulin-pump-featuring-its-first-smartphone-controlled-design-302716864.html   XX Lots of new out of the recent ATTD conference.. some headlines: New study from the UK shows that Ketone Monitoring Could Significantly Reduce DKA Risks in people with type 1 and type 2. This was a study by Abbott which recently submitted a continuous dual glucose-ketone monitor to the FDA for clearance – if approved, it could be available in the U.S. later this year. -- The first modified insulin producing cells are still working 14 months after transplant – without the need for immunosuppressive drugs. This is from Sana which now plans a study of a new therapy.. same gene-editing strategy with lab-grown, stem-cell-derived insulin-producing cells. -- Protein looks like it helps avoid lows during exercise. Both high and low doses of whey protein before exercise were effective, significantly reducing the risk of hypoglycemia by five to 10 times.   Researchers noted that the body's response to protein was rapid (within 20 minutes), which suggests taking it close to the beginning of exercise could be beneficial for preventing hypoglycemia. Though more research is needed, there was also evidence showing protein intake could be beneficial for prolonged fasting and preventing overnight lows. -- More info about type 1 and GLP medications. Researchers at ATTD presented the results of a small, seven-month study assessing the effectiveness of semaglutide for people with type 1 diabetes and obesity. During the trial, 36% of participants taking semaglutide spent more than 70% of their time in range, less than 4% of their time below range, and lost more than 5% of their body weight compared to those not taking semaglutide.   Treatment with semaglutide was also associated with reductions in cholesterol and blood pressure. Based on all of these changes, the researchers calculated that the participants who received semaglutide had significantly reduced their risk of heart disease over the next 10 years.   Other studies show that since 2020, prescriptions of GLP-1 medications have grown exponentially for adults with type 1 diabetes between the ages of 18 and 85. https://diatribe.org/diabetes-research/top-diabetes-news-attd-2026   XX Lots of talk about fully closed loops.. CamDiab unveiled theirs.. called Liberty.. which the company says it's the world's first fully closed loop commercial launch. CamDiab offers the FDA-approved mylife CamAPS FX app for automating insulin delivery in MyLife's (formerly Ypsomed Diabetes Care's) insulin delivery pumps. The mylife CamAPS FX on iOS has full compatibility with leading continuous glucose monitors (CGMs). Those include the FreeStyle Libre 3 and Libre 3 Plus from Abbott and the Dexcom G6 so customers can use their preferred device. https://www.drugdeliverybusiness.com/camdiab-unveils-fully-closed-loop-insulin-feature/ XX Insulet reported data on a fully closed-loop automated insulin delivery system in people with Type 2 diabetes. The 24 people in the trial spent 24% more time in the target blood glucose range using the system than when receiving standard injection therapy. Insulet plans to start a pivotal study this year and aims to launch in 2028. Rival insulin pump manufacturer Tandem is on a similar course. Tandem CEO John Sheridan told investors on an earnings call last month that his team plans to start a pivotal trial this year to support a filing with the Food and Drug Administration in 2027. Medtronic disclosed the start of a pivotal trial of its Vivera fully closed-loop algorithm last month, shortly before spinning off the program as part of the MiniMed initial public offering. The algorithm, which is designed to eliminate carb counting and manual food bolusing, achieved a mean time in range of 73.8% without manual user input in a feasibility study.   https://www.medtechdive.com/news/insulet-posts-clinical-data-on-fully-closed-loop-insulin-delivery-system/814516/ XX Congrats to all honored by the 2026 National Scientific and Health Care Achievement Awards from the American Diabetes Association! Shout out to Diana Isaacs, PharmD, BCACP, BC-ADM, CDCES: 2026 Outstanding Educator in Diabetes Award and to  Korey Hood who receives the Richard Rubin award. Dr. Rubin was a pioneer in behavioral science and committed to keeping the person with diabetes at the center of research and care.

Ever wondered why no new 8(a) companies are being approved—and what that means for your government contracting strategy? In this episode, we break down the current 8(a) program freeze and what it means for small businesses trying to break into federal contracting. Despite the slowdown in approvals, opportunities are still flowing—and in some cases, increasing. We dive into how experienced contractors are navigating this challenge, including creative strategies like joint ventures, partnerships, and even transferring ownership of existing 8(a) companies to stay competitive. You'll learn: Why 8(a) approvals have stalled and what the data actually shows How to leverage existing 8(a) companies to access sole-source contracts Why attending industry events and networking is still the fastest path to opportunities If you're serious about winning government contracts, this episode will help you pivot, adapt, and stay ahead—no matter what changes happen in the program. If you want to learn more about the community and to join the webinars go to: https://federalhelpcenter.com/ Website: https://govcongiants.org/ Connect with Encore Funding: http://govcongiants.org/funding

Conrad Black Conrad Black discusses Prime Minister Mark Carney's commitment to defending the Northwest Passage with military investment. He highlights how pipeline project approvals serve as a vital litmus test for maintaining Canadian national unity. Carney's Arctic Defense and the Pipeline Litmus Test (1)1932 COMMONS OTTAWA

The global medical device regulatory environment is complex, often requiring manufacturers to repeat similar submissions and audits across multiple countries. This duplication slows innovation and delays patient access to life-saving technologies.To address this challenge, international regulators are increasingly collaborating through the International Medical Device Regulators Forum (IMDRF).In this podcast episode, Stephanie Grassmann (MedTechXperts) joins us to discuss how the concept of Regulatory Reliance is transforming global medical device approvals.What is IMDRF?The International Medical Device Regulators Forum (IMDRF) is a voluntary group of regulatory authorities working together to harmonize medical device regulations and reduce duplication across global markets.Members include major regulatory bodies such as:• United States (FDA)• European Union• Australia (TGA)• Brazil (ANVISA)• Canada (Health Canada)• China (NMPA)Their mission is to promote efficient regulation while maintaining high standards of safety and performance.Understanding Regulatory RelianceRegulatory reliance allows one authority to give significant weight to the work already performed by another trusted regulator.Instead of repeating full assessments, authorities can leverage existing evaluations, reducing regulatory burden while maintaining confidence in safety and effectiveness.Real-World Success StoriesSeveral regulators are already demonstrating the benefits of reliance mechanisms.Australia – TGAA Class III Mitral Valve Clip reached market access in just 20 working days after the regulator accepted evidence generated overseas.Argentina – ANMATDental instruments known as endodontic barbed broaches were approved in 9 working days using reliance pathways.Brazil – ANVISACompanies holding MDSAP certification may skip immediate on-site audits, saving both time and money during market entry.These examples show how regulatory cooperation can significantly accelerate approvals.The Role of MDSAPThe Medical Device Single Audit Program (MDSAP) allows manufacturers to undergo a single regulatory audit recognized by multiple countries.This program plays a key role in enabling reliance between regulatory authorities and reducing redundant inspections.The European PerspectiveEurope has historically maintained a distinct regulatory framework under EU MDR and IVDR.However, recent proposals—including references to Articles 108a and 108b—suggest increasing collaboration with international frameworks such as IMDRF and MDSAP.While a single global approval system remains a long-term goal, reliance initiatives are already demonstrating that cooperation between regulators can improve efficiency without compromising safety.Looking AheadFor manufacturers and startups, embracing international regulatory frameworks early—such as MDSAP and IMDRF guidance—can significantly improve global market access strategies.As regulatory collaboration grows, the future of medical device approvals may become faster, more harmonized, and more patient-centered.Who is Monir El Azzouzi? Monir El Azzouzi is the founder and CEO of Easy Medical Device a Consulting firm that is supporting Medical Device manufacturers for any Quality and Regulatory affairs activities all over the world. Monir can help you to create your Quality Management System, Technical Documentation or he can also take care of your Clinical Evaluation, Clinical Investigation through his team or partners. Easy Medical Device can also become your Authorized Representative and Independent Importer Service provider for EU, UK and Switzerland. Monir has around 16 years of experience within the Medical Device industry working for small businesses and also big corporate companies. He has now supported around 100 clients to remain compliant on the market. His passion to the Medical Device filed pushed him to create educative contents like, blog, podcast, YouTube videos, LinkedIn Lives where he invites guests who are sharing educative information to his audience. Visit easymedicaldevice.com to know more.  If you need help implementing QMSR or preparing your teams for FDA inspections, contact: info@easymedicaldevice.com If you are located outside the EU/UK/Switzerland and need an Authorized Representative (and possibly an Importer), we can support you as well.LinkStephanie Grassmann Linkedin: https://www.linkedin.com/in/stephaniegrassmann-medtechxperts/Social Media to followMonir El Azzouzi Linkedin: https://linkedin.com/in/melazzouziTwitter: https://twitter.com/elazzouzimPinterest: https://www.pinterest.com/easymedicaldeviceInstagram: https://www.instagram.com/easymedicaldeviceThis podcast is powered by Podcastics, the easiest platform to create and publish your podcast.

Ryan and I discuss how to use MTRX for to get more approvals for your jobs and earn more Money in your business. Most of you have this tool. It's time to learn how to use it to its max potential! www.dentprosacramento.com  

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll delve into a series of remarkable advancements and regulatory evolutions shaping the landscape of medicine.One of the most significant recent developments involves Boehringer Ingelheim's drug Hernexeos, which has seen a rapid expansion in its use as a first-line treatment for non-small cell lung cancer (NSCLC). This expansion was made possible through the FDA's Commissioner's National Priority Voucher, an initiative designed to fast-track the approval of treatments addressing critical needs. This rapid progression highlights a commitment to accelerating access to crucial oncological treatments, emphasizing the role of accelerated regulatory pathways in swiftly delivering innovative therapies to patients who need them the most.In oncology, a combination therapy involving Padcev and Keytruda is showing promising results in improving overall survival rates for patients with muscle-invasive bladder cancer who are eligible for cisplatin. However, the continuously evolving landscape of treatment options for this cancer type means that further evaluation is necessary. This scenario highlights the ever-changing nature of oncology strategies and the ongoing need for clinical validation to determine the most effective treatment regimens.Switching gears to immunology, UCB's Bimzelx has reached a significant sales milestone, reflecting its growing influence in treating multiple indications. This success points to an expanding market for immunology therapeutics, as the industry remains focused on developing blockbuster treatments that can serve various conditions effectively.On the regulatory front, Moderna's combination influenza/COVID-19 vaccine has received a positive review from the European Medicines Agency's Committee for Medicinal Products for Human Use. This green light exemplifies the EU's dedication to thorough scientific evaluations. It contrasts with the FDA, which has exhibited hesitancy in this area, highlighting how varying regulatory approaches can affect drug availability in different regions.The field of HIV treatment is also seeing progress with GSK's ViiV division confirming the efficacy of its long-acting Cabenuva regimen for adolescents over a 96-week period. This long-acting regimen provides an alternative to daily oral therapies, potentially improving adherence and outcomes among younger populations—a crucial factor in managing chronic conditions effectively.Meanwhile, legal developments are stirring as the debate over "skinny labeling" for generic drugs reaches a pivotal point. The U.S. Supreme Court is being urged to overturn a ruling that endangers this pathway, highlighting the fine balance between fostering generic drug competition and protecting pharmaceutical innovation. In related legislative discussions, a Senate hearing focused on the FDA's rare disease review process has brought to light concerns about bureaucratic obstacles that may slow innovation. There is a call from stakeholders for more streamlined processes to ensure timely access to treatments for rare diseases—a sentiment echoed by many in the industry.The burgeoning field of CAR-T cell therapies continues to make waves, especially against solid tumors. Recent preclinical studies have shown potential efficacy in eradicating solid tumors in mice models. Despite these promising findings, significant regulatory challenges remain, and streamlining approval processes could accelerate their clinical application.In other significant news within the industry, Novartis has completed its acquisition of Avidity Biosciences for $12 billion, leading to the creation of Atrium Therapeutics. With a capitalization of $270 million, Atrium emerges with two promising preclinical candidates targeting cardiovascular conditions, signaling potential advSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a range of transformative events shaping the industry, from regulatory approvals and licensing deals to clinical trial outcomes and strategic partnerships, each carrying profound implications for drug development and patient care.Starting with the biopharma landscape in China, there's a notable shift in the valuation of licensing deals, which have seen a significant increase of 230% in upfront payments. This surge, from $52 million to $172 million between 2022 and early 2026, signals China's growing influence and competitiveness in the sector. Historically considered a low-cost option for licensing deals, China's enhanced innovation capabilities are now attracting Western companies seeking strategic collaborations. The implications are vast, offering Western firms an opportunity to tap into China's expansive market potential and leverage local expertise, underscoring the country's pivotal role in global drug development.In regulatory news, Pfizer's Braftovi (encorafenib) combination therapy has achieved full FDA approval for colorectal cancer treatment. This is a critical development, expanding therapeutic options for a particularly challenging cancer type. The approval highlights the increasing importance of targeted therapies in oncology, reflecting ongoing efforts to address unmet medical needs by enhancing the treatment arsenal available to clinicians. As cancer remains a major global health issue, such advancements are vital for improving patient outcomes.Novartis is making headlines with its substantial investment strategy to boost radiopharmaceutical production capabilities in the United States. With new manufacturing sites planned in Texas and Florida as part of a broader $23 billion investment, Novartis is positioning itself at the forefront of radiopharmaceuticals—a field offering innovative cancer treatments through targeted radiation delivery. This strategic move not only strengthens Novartis's presence in this burgeoning field but also signifies a broader industry trend towards cutting-edge technologies that promise more precise and effective treatment modalities.Shifting focus to drug pricing dynamics, Novo Nordisk has announced plans to reduce list prices for its GLP-1 medications, Ozempic and Wegovy, starting next year. While self-pay channels remain unaffected, this price reduction reflects broader industry trends towards addressing medication costs amidst mounting pressure from healthcare stakeholders. The move aims to enhance affordability for diabetes and obesity treatments, crucial given the rising prevalence of these conditions globally.In gene therapy, BioMarin has faced challenges with its hemophilia A gene therapy, Roctavian. Despite potential clinical benefits, BioMarin's efforts to divest the therapy have resulted in a $240 million financial setback. This scenario underscores the inherent complexities and financial risks associated with developing advanced therapies like gene therapies. Meanwhile, Pfizer has shown continued interest in gene editing technologies by securing global rights to Beam Therapeutics' liver-targeted gene editing candidate. This decision marks Pfizer's strategic pivot towards promising frontiers in therapeutic innovation.Emerging biotech BreezeBio has rebranded and secured $60 million in funding to advance its research in genetic medicine focused on restoring immune tolerance in type 1 diabetes. This strategic pivot towards addressing autoimmune diseases using innovative genetic approaches highlights ongoing efforts within the biotech sector to tackle complex health challenges through cutting-edge science.Collectively, these developments illustrate dynamic trends within the pharmaceutical and biotech sectors: a shift towards more equitable global partneSupport the show

Patrick Carino shares how he sources ground-up multifamily deals, navigates Northeast development, and built DealNav out of his Excel frustration. The Crexi Podcast connects commercial real estate (CRE) professionals with industry insights built for smart decision-making. In each episode, we explore the latest trends, innovations and opportunities shaping commercial real estate, because we believe knowledge should move at the speed of ambition and every conversation should empower professionals to act with greater clarity and confidence.   In this episode, host Shanti Ryle sits down with Patrick Carino, Vice President of Development at the NRP Group, to discuss the latest trends, insights, and strategies shaping multifamily development across the Northeast. They explore Patrick's unconventional path into real estate — starting with punch lists in high school — through his years at CBRE and into his current role sourcing and executing ground-up developments across New York, New Jersey, Connecticut, and Massachusetts. They also delve into Patrick's strategic approach to cold outreach and job hunting, the nuances of buying land that is subject to approvals, and what macro forces are reshaping deal economics today. Patrick also shares the origin story of DealNav, the map-based CRM he built for himself that accidentally became a product — and why he believes a human touch is still best for finding deals. Guest Introduction: Patrick Carino Starting in Real Estate in High School From Spec Homes to Multifamily Leasing Studying Real Estate at UConn Landing at CBRE's New York Institutional Group Learning the Market Through Deal Volume A Strategic Approach to Job Hunting and Cold Outreach How to Stand Out in Networking Conversations The Role Patrick Built at NRP Group Specialist vs. Generalist Models in Development How NRP's Teams Collaborate Across the Deal Lifecycle Deal Sourcing Criteria: Land, Size, and Approvals Buying Subject to Approvals — and Why It Matters Three Ways Patrick Sources Deals What Can Make or Break the Entitlement Process How Rates, Tariffs, and Regulations Affect the Northeast Market-by-Market: New York, New Jersey, and Massachusetts What Keeps Patrick Up at Night — and What Excites Him Why Passion and Patience Are Essential in Development The Origin Story of DealNav Building a Simple, Map-Based CRM for Deal Tracking How Twitter Led to an Accidental Product Launch DealNav's Roadmap: Custom Fields, Map Features, and Integrations Why DealNav Doesn't Use AI — and Why That's Intentional Rapid Fire: Investment Picks, Worst Advice, and Parting Wisdom For show notes, past guests, and more CRE content, please check out Crexi's blog.Looking to stay ahead in commercial real estate? Visit Crexi to explore properties, analyze markets, and connect with opportunities nationwide. Follow Crexi:https://www.crexi.com/​ https://www.crexi.com/instagram​ https://www.crexi.com/facebook​ https://www.crexi.com/twitter​ https://www.crexi.com/linkedin​ https://www.youtube.com/crexi

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a compelling array of advancements and strategic shifts that are shaping the healthcare landscape across the globe.In recent times, the pharmaceutical and biotech sectors have showcased remarkable resilience and innovation, driving forward with significant scientific breakthroughs and clinical trial results. A standout achievement comes from Novo Nordisk, whose recent Phase 2 trial results for its triple agonist targeting obesity reported a remarkable weight loss of up to 19.7% in patients over 24 weeks. This promising development positions Novo Nordisk as a formidable contender in the obesity treatment market, potentially affecting giants like Eli Lilly. With obesity being a significant global health challenge, these findings underscore the potential of multi-targeted approaches in managing this complex condition.Regulatory landscapes continue to evolve, with pivotal approvals marking milestones for therapies targeting rare diseases. Immedica Pharma's Loargys received FDA approval for treating hyperargininemia associated with arginase 1 deficiency, highlighting perseverance in overcoming regulatory hurdles after a prior rejection. Additionally, Sanofi and Regeneron's Dupixent achieved its ninth FDA approval, underscoring its versatile potential across multiple indications. These approvals not only reflect regulatory progress but also emphasize the critical role of persistence in drug development.Ethical considerations remain at the forefront of industry discussions, particularly highlighted by Novartis' settlement in a lawsuit concerning the use of Henrietta Lacks' cells without consent. This resolution underscores ongoing ethical challenges within biomedical research, emphasizing the need for ethical vigilance as companies increasingly rely on human-derived materials.Significant business trends are shaping strategic directions within the industry. Pfizer's acquisition of marketing rights for Sciwind's GLP-1 receptor agonist in China exemplifies a calculated move to dominate the obesity treatment market. This strategic acquisition allows Pfizer to leverage China's vast market potential for type 2 diabetes medications and positions it favorably for future weight loss treatments.On the manufacturing front, AbbVie has made substantial investments in U.S. infrastructure, committing $380 million to new North Chicago API plants as part of a decade-long strategy to inject $100 billion into U.S. operations. This initiative highlights a commitment to bolstering domestic production capabilities amidst global supply chain uncertainties.The complexities of drug development are further illustrated by Roche's decision to halt the development of Enspryng for Duchenne muscular dystrophy due to unsatisfactory progress. This shift in focus reflects the inherent challenges of drug repurposing and the necessity of robust clinical evidence to support new indications.Geopolitical factors also play a significant role in shaping industry dynamics, with recent U.S. Supreme Court decisions impacting international trade agreements. Such geopolitical influences can significantly affect pharmaceutical companies' operations and strategic planning.The collaboration between Astellas and Vir Biotechnology reflects another significant trend in strategic partnerships within the industry. Their $1.7 billion deal centered on a novel bispecific T-cell engager for prostate cancer underscores the growing importance of immuno-oncology and innovative approaches to targeting hard-to-treat cancers.The regulatory front continues to see transformative changes with the FDA unveiling draft guidance for a new approval pathway tailored for bespoke gene-editing therapies. This initiative could expedite personalized genetic treatments and transform patSupport the show

Benson officials face a March 6 deadline to answer state investigators as the Attorney General’s office keeps digging into whether the city’s Planning and Zoning Commission followed Arizona’s open meeting rules during key votes on the Aluminum Dynamics permit.Support the show: https://www.myheraldreview.com/site/forms/subscription_services/See omnystudio.com/listener for privacy information.

Alexander Embiricos is the Head of Codex at OpenAI, leading the development of the company's flagship AI coding systems that power automated software generation, debugging and developer workflows. Under his leadership, Codex has become one of the most widely adopted AI developer platforms.  AGENDA: 05:13 Will Coding Be Automated? Why AI Could Create More Engineers, Not Fewer 07:17 Do We Need PMs? The "Undefined" Product Role and When It Matters 08:06 The Real AGI Bottleneck: Human Prompting, Validation, and "Too Much Effort" 13:04 Three Phases of Agents: Coding → Computer Use → Productized Workflows 13:52 Enterprise Reality Check: Security, Permissions, and Safe Agentic Browsing 17:57 Is Inference the New Sales and Marketing?  18:49 What % of Codex Was Written by AI? 21:33 Do OpenAI Use AI for Code Review? 23:31 Is there any stickiness to AI coding tools? 28:22 What Does "Winning" Mean at OpenAI? Mission, Competition, and Moats 32:04 The Future UI: Chat or Voice 34:10 Agent-to-Agent Workflows: Designing for Approvals, Compliance, and Automation 35:39 Do Coding Models Have a Data Moat? 36:50 How does Codex View Data: Will They Build Their Own Mercor and Turing? 37:27 How Does Codex View Consumer: Will They Compete with Lovable? 41:56 Benchmarks vs "Vibes": How People Actually Judge Models 42:43 Cursor's Edge and the Case for Building Your Own Models 47:37 Is SaaS Dead? What Still Defends Value (Humans + Systems of Record) 51:28 Talent Wars and Career Advice for New Engineers in the AI Era 01:01:03 Guardrails, the Fully AI-Managed Stack, and a 10-Year Vision for Everyone      

Guest: Bob Zimmerman. Musk announces SpaceX will prioritize the Moon before Mars; regulatory approvals for Starship launches are pending, while Voyager Space secures a management contract for ISS operations.1906. WELLS. MARTIAN

What does it take to win a competitive retail LOI today?Retail leases are moving fast again, and in East Tennessee, they are moving faster than most people think is possible.Chris Ressa talks with Lindsey Barden, founder of Dark Horse CRE, a tenant-rep-only broker covering Knoxville, Chattanooga, and the Tri-Cities. Her view from the ground is simple: vacancy is extremely low, the best spaces trade off-market, and retailers are routinely battling multiple LOIs for the same box. In the past six months, Lindsey says 80-to-90 percent of her deals have been competitive, forcing brands to show up ready to commit, pay closer to asking, and cut through internal red tape.Landlords are prioritizing certainty and speed, especially in second-generation space. The tenants winning deals are the ones asking for less work and fewer dollars from ownership, tightening timelines, and moving from “perfect protections” to more balanced lease terms.The proof point is a Crunch Fitness anchor lease that went from discovery to signed lease in roughly two weeks. No traditional LOI. Basic terms handled by email. Architects and contractors brought in immediately. Approvals happening across time zones. A two-level layout that required creative planning, not a cookie-cutter prototype. Two motivated parties decided the deal mattered, and executed like it.If you want a takeaway: stop treating leasing like a slow process. Treat it like a race. Speed wins.What You'll HearWhy East Tennessee is one of the tightest retail markets in the country — and what low vacancy really means for tenants trying to expand.What 80 to 90 percent competitive deal flow looks like in practice — multiple LOIs, limited second-generation space, and constant off-market conversations.How landlords are prioritizing certainty over creativity — why minimal TI, faster approvals, and fewer contingencies are winning deals.What retailers must change internally to compete — consolidating corporate review, accelerating decision-making, and committing earlier.How a Crunch Fitness anchor lease went from tour to signed in 14 days — no traditional LOI, creative problem solving on a two-level box, and approvals happening across time zones.Why speed is the ultimate differentiator in today's leasing environment — and how motivated parties can compress timelines dramatically.A thoughtful look at retail saturation vs. market expansion — coffee, chicken, gyms, and how to separate durable concepts from passing trends.The mindset shift required to win in 2026 retail real estate — treat leasing less like a negotiation marathon and more like a sprint.Chapters00:00 – Meet Lindsey BardenA 20-year tenant rep veteran shares her journey from Virginia brokerage to founding Dark Horse CRE in East Tennessee.08:15 – Why East Tennessee Is So CompetitiveLindsey breaks down Knoxville's low vacancy,...

Thanks to our Partners, NAPA TRACS, Today's Class, KUKUI, and Pit Crew Loyalty Watch Full Video Episode Reaching 250,000 miles on a vehicle isn't luck—it's leadership. In this episode, we explore what long-term vehicle maintenance really looks like and why today's shops must rethink how they communicate with customers. Too often, maintenance is treated as a series of isolated repairs. This conversation reframes it as a strategic process built on education, transparency, planning, and advocacy. In this episode, you'll discover how to: Shift your shop culture from reactive repairs to proactive planningPosition service advisors as educators and advocatesUse cost-per-mile analysis to demonstrate real vehicle valueBuild trust through professional language and clear expectationsAlign inspections with long-term ownership goalsImprove maintenance acceptance without fear-based sellingCreate systems that support consistent follow-up Key Discussion Topics Why 250,000-mile vehicles are built through strategy, not chanceThe difference between transactional service and advisory leadershipUsing documentation and trends to guide decisionsStructuring pay plans to reinforce professionalismTurning maintenance into a long-term relationship Why This Episode Matters When customers understand that their vehicle can realistically reach 250,000 miles with the right care, everything changes. Trust improves. Approvals become easier. Loyalty deepens. And your shop evolves from a repair facility into a long-term partner in vehicle ownership. This episode shows how sophisticated professionalism, consistent processes, and education-first communication can transform both customer relationships and business performance. Brett Beachler, Beachler's Vehicle Care & Repair, Peoria, IL. Listen to Brett's previous episodes HERE Rena Rennebohm, CEO and Creator of Empowered Advisor. Rena's previous episodes 

In episode #97 of “The Weekly Bioanalysis” podcast, John and Dom focus on a review of 2025 drug approvals, revealing a surprisingly strong year for small molecules despite long-standing predictions of their decline. Of the 53 FDA approvals, 31 were small molecules, with additional complexity coming from ADCs and RNAi therapies, underscoring the continued importance of small-molecule development and analytics. The hosts also compare U.S. and European approvals, noting meaningful differences driven by regulatory timing and regional priorities rather than scientific divergence. They highlight encouraging momentum in ADCs, the role of acquisitions in successful approvals, and a broad mix of indications—from rare diseases and oncology to neurology and vaccines. Overall, the episode reinforces that innovation remains diverse, with small molecules, large molecules, and conjugated technologies all playing critical roles in modern drug development. If you want a comprehensive view of the noteworthy approvals from 2025, this is the episode you're looking for!“The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio.KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.

With FedRAMP 20x and the 2026 Phase 2 pilot, the government is moving toward automation, machine-readable evidence, and collaborative monitoring. We'll explore what these changes mean for SaaS providers and how companies can cut costs and timelines without sacrificing security with Irina Denisenko, CEO of Knox Systems.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In early 2025, the FDA was rocked by sweeping layoffs and leadership turnover, raising questions about whether the agency could maintain its pace in reviewing new drug applications. By the end of the year, the approval picture told a more complicated story, with momentum building after a slow start. This week on "The Top Line," we dig into what the numbers really show, which companies and therapies came out on top, and what the FDA’s performance over the course of 2025 signals for the drug review process going forward. To learn more about the topics in this episode: 2025 drug approvals: Despite FDA tumult and macro uncertainty, biopharma scored with 55 new products 2024 drug approvals: Small companies loom large with several key FDA nods 2023 drug approvals: After a down year, FDA signs off on a bounty of new meds, including 7 from Pfizer See omnystudio.com/listener for privacy information.

Part 3 of Jen Suzuki's 4-part manager mini-series goes deep into one of the most profitable coaching skills in the dealership: teaching teams how to gain more service approvals using her formula called Job–Risk–Reward (JRR). Jen breaks down exactly how to train advisors, salespeople, and BDC agents to explain value simply, clearly, and with confidence — without scripts. You'll learn how to teach the formula in minutes, demonstrate it live, then drive real application with team exercises, role-play, and even spicy contests that make learning stick. From wipers and brake pads to leather seats and display screens, Jen shows you how this formula boosts trust, increases transparency, and gets customers saying yes more often. This is your playbook for fast, high-impact coaching that drives approvals, customer loyalty, and profitability. Dealer Talk with Jen Suzuki Podcast |

In March 2022, Dr. Joseph Fraiman taped an internal call between FDA directors and physicians who were concerned about mRNA side effects in their patients – including the cardiac arrest and sudden death of a 7-year-old days after being injected with Pfizer's mRNA vaccine. “This was a top level meeting of directors,” Dr. Fraiman revealed to Ask Dr. Drew in Sept 2023. “This entire meeting terrified my entire work group.” The call – legally recorded by Dr. Fraiman – included FDA Director Dr. Peter Marks, Dr. Peter Doshi, Dr. Celia Witten, Dr. Sarah Walinsky, Dr. Lorrie McNeill, and many other experts. “What they're saying here is they're not doing statistical testing on adverse events. This is really insane to me,” Dr. Fraiman continued. “You know there's a problem if the vaccine group has a higher rate of them.” Dr. Joseph Fraiman, MD is an emergency physician and clinical researcher focused on harm-benefit analysis. He served as Medical Manager of Louisiana's Urban Search Rescue Disaster Task Force 1 and is lead author of a widely known re-analysis of mRNA vaccine serious harms. Follow at https://x.com/josephfraiman Dr. Stephanie Venn-Watson is Co-CEO and Co-Founder of Seraphina Therapeutics. She is a veterinary epidemiologist and author of “The Longevity Nutrient” (March 2025). Her background includes DARPA, the U.S. Navy Marine Mammal Program, and research on nutritional C15:0 deficiencies. Learn more at https://drdrew.com/fatty15 「 SUPPORT OUR SPONSORS 」 • AUGUSTA PRECIOUS METALS – Thousands of Americans are moving portions of their retirement into physical gold & silver. Learn more in this 3-minute report from our friends at Augusta Precious Metals: ⁠⁠⁠⁠https://drdrew.com/gold⁠⁠⁠⁠ or text DREW to 35052 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠• FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • VSHREDMD – Formulated by Dr. Drew: The Science of Cellular Health + World-Class Training Programs, Premium Content, and 1-1 Training with Certified V Shred Coaches! More at https://drdrew.com/vshredmd • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠) and Susan Pinsky (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/firstladyoflov⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠e⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Executive Producers • Kaleb Nation - ⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠ • Susan Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/firstladyoflove⁠⁠⁠⁠⁠⁠⁠⁠ Content Producer & Booking • Emily Barsh - ⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/emilytvproducer⁠⁠⁠⁠⁠⁠⁠⁠ Hosted By • Dr. Drew Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/drdrew⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices